Clinical Trial Update: Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial compares the efficacy and safety of dabigatran, rivaroxaban, and apixaban in patients with non-valvular atrial fibrillation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-valvular Atrial Fibrillation

Drugs mentioned

• Apixaban (apixaban)
• Dabigatran (Dabigatran etexilate)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: National Cheng-Kung University Hospital | Conditions: Atrial Fibrillation | Phase 4 | Status: UNKNOWN